1.The term used to describe a disturbed colonic microflora that leaves patients susceptible to C. difficile infection via a loss of colonization resistance is:

Toxic megacolon

Dysbiosis

Probiotic syndrome

Fecal microbiota dysfunction

2.Risk factors for CDI include all of the following except:

Older age

Recent hospitalization

Exposure to antiviral medication

Lack of anti-toxin antibody response

3.Clinical trials demonstrate that, compared to vancomycin, the use of fidaxomicin in the treatment of CDI resulted in significantly:

Higher overall clinical cure rates

Higher clinical cure rates for moderate-to-severe CDI only

Lower clinical cure rates in patients with mild infection

Lower rates of recurrent infection

4.Clinical evidence supports the use of each of the following to decrease the risk of CDI recurrence rates except:

Fecal microbiota transplantation

Metronidazole

Use of a rifaximin chaser following vancomycin therapy

Use of bezlotoxumab with standard of care

5.According to the latest IDSA/SHEA guidelines, which of the following is not an appropriate treatment choice for a patient with a first recurrent episode of CDI?

Vancomycin PO plus metronidazole IV

Vancomycin standard dosing

Prolonged tapered vancomycin regimen

Fidaxomicin standard dosing

6.Clinical trials demonstrate that antibodies against which of the following toxins can reduce the rate of recurrence of CDI?

Toxin A

Toxin B

Toxin A and B

Binary toxin